Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Inclusion Criteria:

- 18 years or older

- Diagnosis of MDS or CMML

- Diagnosis of AML, Multiple myeloma, Hodgkin's or Non-Hodgkin's lymphoma for whom
standard curative or palliative measures do not exist or are no longer effective

- ECOG Performance Status 0-2

- Use of acceptable birth control

- Standard safety inclusion for serum creatinine, AST, ALT, bilirubin

- Serum bicarbonate greater than or equal to 20 mEq/L

- Platelet count greater than or equal to 25,000/uL

- Hemoglobin greater than or equal to 500/uL

- Signed informed consent

Exclusion Criteria:

- Diagnosis of acute promyelocytic leukemia

- Treatment with demethylating agents within 21 days prior to Cycle 1, Day 1

- Treatment with any anticancer therapy (standard or investigational) within 21 days
prior to Cycle 1, Day 1 or ongoing adverse events from previous treatment

- Hypersensitivity to azacitidine or mannitol

- Active, uncontrolled infection

- Presence of GI disease, malignant tumors or other conditions known to interfere with
ADME

- Known or active HIV, viral hepatitis B or C

- Breastfeeding or pregnant females

- Current or uncontrolled cardiac disease